2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

執行長

Mr. Nick Leschly

員工

437

國家

United States

上市

TSVT.MX

0 Comments

分享你的想法

FAQ

2seventy bio 的股票代號是什麼？▼

根據交易所不同，股票代號可能會有所差異。例如，在交易所，2seventy bio 的股票以代號 TSVT V 進行交易。

2seventy bio 有多少名員工？▼

截至 April 03, 2026，公司共有 437 名員工。

2seventy bio 位於哪個產業？▼

2seventy bio從事於Healthcare產業。

2seventy bio 何時完成拆股？▼

2seventy bio 最近沒有進行任何拆股。

2seventy bio 的總部在哪裡？▼

2seventy bio 的總部位於 United States 的 Cambridge。